Researchers from GIS have previously identified a set of biomarkers, which identify breast cancer patients with higher likelihood of breast cancer relapse within five years.
SINGAPORE (Sept 10): Biolidics has entered into an agreement with the Genome Institute of Singapore (GIS) to collaborate and develop a new and innovative liquid biopsy test in the field of circulating tumour cells (CTCs) for the assessment of minimal residual disease (MRD) and predicting the risk of relapse in women who had breast cancer.
Biolidics is the medical technology company with a focus on cancer diagnostic solutions while GIS is a unit of the Agency for Science, Technology and Research (A*STAR).
